Vicious cycles of mutations and reactive oxygen species (ROS) generation contribute to cancer progression. The use of antioxidants to inhibit ROS generation promotes cytostasis by affecting the mutation cycle and ROS-dependent survival signaling. However, cancer cells select mutations to elevate ROS albeit maintaining mitochondrial hyperpolarization (Δψm), even under hypoxia. From this perspective, the use of drugs that disrupt both ROS generation and Δψm is a viable anticancer strategy. Hence, we studied the effects of mitochondrially targeted carboxy proxyl nitroxide (Mito-CP) and a control ten carbon TPP moiety (Dec-TPP + ) in the human Burkitt lymphoma cell line (Daudi) and normal peripheral blood mononuclear cells under hypoxia and normoxia. We found preferential localization, Δψm and adenosine triphosphate loss, and significant cytotoxicity by Mito-CP in Daudi cells alone. Interestingly, ROS levels were decreased and maintained in hypoxic and normoxic cancer cells, respectively, by Mito-CP but not Dec-TPP + , therefore preventing any adaptive signaling. Moreover, dual effects on mitochondrial bioenergetics and ROS by Mito-CP curtailed the cancer survival via Akt inhibition, AMPK-HIF-1α activation and promoted apoptosis via increased BCL2-associated X protein and poly (ADP-ribose) polymerase expression. This dual mode of action by Mito-CP provides a better explanation of the application of antioxidants with specific relevance to cancerous transformation and adaptations in the Daudi cell line.
Introduction
Cancer is a metabolic disease, the metabolic alterations and proliferation of which are caused by oncogenic mutations and/or oncogenic viruses. Alterations within the cancer niche are not coordinated with the surrounding normal cells; this affects their homeostasis [1] . Daudi immortalization of normal B-cells into the Daudi cell line involves the cellular transformation termed Latency III [2, 3] . This is mediated by EBV proteins, including five nuclear proteins (EBNA-1, -2, -3, -5, and -6) and one latent membrane protein (LMP-1) [4, 5] . For example, Epstein-Barr nuclear antigen 1 (EBNA 1), a regularly detected protein of all EBV-associated malignancies, transcriptionally activates the expression of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) oxidase 2 (NOX2), a key generator of reactive oxygen species (ROS) that is elevated under Latency III [6, 7] . This elevated ROS response mediated by EBV promotes activation of Akt, by oxidation-reduction (redox) inhibition of its phosphatase (PP2A), and helps to counteract apoptosis and favor cell survival. This is highlighted by the fact that ROS scavengers (such as N-acetyl-L-cysteine [NAC] , catalase, and reduced glutathione) have been shown to have positive effects in inhibiting EBV reactivation [8] . Moreover, EBNA-5 and -3 have been shown to bind and inhibit prolyl hydroxylases 1 and 2, respectively. This leads to activation of hypoxia-inducible factor 1-alpha (HIF1-α) and results in a metabolic reprogramming associated with HIF1-α responsive genes (such as [9] . Thus, the net adaptive strategies of EBV-transformed Daudi cells involve key cellular mediators Akt and HIF1-α, of which the former lies in the upstream regulation of the later. A promising strategy to divert EBV cellular immortalization in Daudi cells towards apoptosis is to target Akt activation through the cell-specific delivery of antioxidants.
In the context of specificity, the endogenous mode of specific antiviral response via type 1 interferon has been shown to decrease the activities of cytochrome c oxidase and NADH (nicotinamide adenine dinucleotide)-cytochrome c reductase, leading to the inhibition of mitochondrial electron transport and, hence, decreasing cellular adenosine triphosphate (ATP) levels in the Daudi cells hindering its proliferation. This highlights the importance of mitochondrial bioenergetic's influence on the proliferation of Daudi cells, as well as cancers derived from oncogenic mutations [10] . Interestingly, cancer cells maintain optimal mitochondrial electron transport chain (ETC) function, even under oxygen level conditions as low as 0.5%. Maintenance of a distinct hyperpolarized state of mitochondria under both normoxic and hypoxic conditions offers an attractive strategy to selectively delivering antioxidant moieties into cancer cells [11, 12] . As such, we investigated the mode of action of a mitochondrial membrane potential dependent antioxidant (Mito-CP) on cancerous Daudi cells and normal peripheral blood mononuclear cells (PBMCs). Moreover, since localized hypoxia in various tissues (such as lymph node, colon, and liver) promotes organ-specific homing and tumor spreading [13] , we were also keen to understand the effect of Mito-CP under hypoxic conditions.
In the present study, we found that Mito-CP treatment under hypoxia and normoxia induces significant high toxicity and apoptosis in Daudi cells than in PBMCs. Further, we found the increase in apoptosis with Mito-CP treatment under hypoxia and normoxia was associated with increased mitochondrial localization, and decreased mitochondrial membrane potential and ATP production in Daudi cells than in PBMCs. Interestingly, ROS levels decreased and were maintained in hypoxic and normoxic Daudi cells, respectively, therefore preventing any adaptive signaling via Akt. Regulation of ROS, ATP, Akt and AMPK by Mito-CP was accompanied by a decrease in hypoxia-inducible factor 1-alpha (HIF-1α) and an increase in apoptotic markers such as poly(ADP-ribose) polymerases (PARP) and cytochrome C (cyt c) in Daudi cells than in PBMCs. Hence, this study elucidates that Mito-CP is an effective chemotherapeutic agent whose selective localization induces apoptosis in Daudi cells, than in PBMCs, by a dual-mode mechanism involving its effects on mitochondrial bioenergetics and antioxidant effects that cumulatively prevent survival through Akt signaling. To validate Mito-CP's use for anticancer therapy, its dual anticancer activity mechanisms can be further evaluated in vivo and in cancers with similar survival strategies.
Materials and methods

Drug and cell culture
Mito-CP was obtained from Dr. Balaraman Kalyanaraman's lab (Department of Biophysics and Free Radical Research Center, Medical College of Wisconsin, Milwaukee, USA), with whom we are collaborating on the present work. The hypoxia chamber was purchased from Eppendorf India (Chennai, India). Daudi cells (human B lymphoblast cells) were purchased from the National Centre for Cell Science (Maharashtra, India) and maintained in Gibco RPMI-1640 (Life Technologies, Grand Island, New York, USA) medium with 100 U penicillin/ml (HiMedia Laboratories, LBS Marg, Mumbai, India), 100 μg streptomycin/ml (HiMedia Laboratories, LBS Marg, Mumbai, India) and 10% fetal bovine serum (FBS) (Life Technologies, Grand Island, New York, USA), Dec-TPP + (Sigma Aldrich, St.louis, Missouri.)
The study has been approved by the Anna University Institutional Ethical Review Board (AU-IERB) and Anna University Institutional Biosafety Committee (AU-IBSC) Centre for Biotechnology, Anna University, Chennai, Tamilnadu, India and all the subjects gave written informed consent. Blood used to isolate PBMC was collected from healthy human volunteers using a heparinized syringe. PBMC was isolated from 20 mL of normal human blood by HiSep LSM 1077 Ficoll solution (HiMedia Laboratories, LBS Marg, Mumbai, India) taken in a sterile Falcon tube. Blood was slowly added to the Ficoll solution tube, in a slanted position, in a 2:1 ratio. Cells were spun at 448 g for 20 min. at 4˚C. Buffy coat was removed carefully and collected in a fresh Falcon tube. Again, the cells were spun at 448 g for 15 min. at 4˚C. The supernatant was discarded, and the pellet was washed in 5 mL of incomplete RPMI medium (without FBS). Cells were spun at 252 g for 10 min, and the supernatant was discarded and resuspended in 1 mL of completed RPMI medium with 10% FBS. Cells were counted by taking 10 μL of cells and 10 μL of Gibco trypan blue stain (Life Technologies, Grand Island, New York, USA) in a haemocytometer [14] .
Cell treatment
On the day of treatment, Daudi cells and PBMCs were grown to 1x10 6 
Cell proliferation
The cells' proliferation rate was analyzed with the alamarBlue reagent (Invitrogen, Frederick, MD, USA). Each well of 96-well plate was seeded with 3,000 cells, and all were subjected to hypoxia with and without Mito-CP treatment. Cells after treatment were incubated for 24 h. Then, 10 μL of the alamarBlue reagent was added and the cells were incubated for an additional 8 h. Absorbance was read at 570 nm in an ELISA plate reader.
Apoptosis assay using Annexin V-FITC and propidium iodide
Daudi cells and PBMC's were grown to and subjected to treatment under hypoxia and normoxia with and without Mito-CP (1 μM), as described previously. Suspension cells were centrifuged, and the pellet was washed twice with PBS (phosphate-buffered saline). Cell density was determined and diluted to approximately 4x 10 5 cells/ml and stained with a combination of 10 μL Annexin V-FITC conjugate and 1 μL of propidium iodide according to the kit protocol (Molecular Probes, Eugene, OR, USA), and the fluorescent images were scanned using confocal laser scanning microscopy. The co-localization fluorescence intensity of both annexin V-FITC and propidium iodide were quantified using image J software.
ATP production assay
Cellular ATP content was analyzed to determine the bioenergetics of the Daudi and normal PBMC's. Cells subjected to treatment of hypoxia, with and without treatment of Mito-CP, were seeded, and intracellular ATP levels were determined using a bioluminescence-based assay as per the manufacturer's protocol (Molecular Probes, Eugene, OR, USA). Luminescence were measured by luminescence plate reader (BioTek Instruments, Winooski, VT, USA).
Detection of reactive oxygen species
ROS (hydrogen peroxide) release was measured with an Amplex Red reagent (Molecular Probes, Eugene, OR, USA) according to the manufacturer's protocol. Cells subjected to hypoxia, with and without treatment of Mito-CP, and 20 μl of approximately 2x 10 4 Daudi and PBMC's suspended in Krebs ringer phosphate buffer were added to a 96-well plate along with 100 μL of reaction mixture containing 50 μM Amplex Red reagent and 0.01 uHRP/mL in a Krebs ringer phosphate buffer and incubated at 37˚C for 10 min. Readings were taken in an ELISA plate reader at 560 nm.
Mitochondrial membrane potential
Daudi cells and PBMCs were seeded in a 96-well plate at a density of 6×10 4 cells per well in 100 μL medium in triplicate. Cells were treated under hypoxia and normoxia without and without Mito-CP. After treatment, 10 μL JC-1 dye solution (Cayman Chemicals, USA, catalogue no. 10009908) was added to each well and cells were incubated for 30 min. Next, cells were washed twice with an assay buffer by centrifuging at 400g for 5 min. and resuspended in a 200 μL assay buffer according to the manufacturer's protocol. Then, the plate was read for fluorescence intensity using a fluorescent plate reader with excitation and emission, respectively, at 535 nm and 595 nm for J aggregates and 485 nm and 535 nm for J monomers. , C = 60˚, C 20 = 2.00 [16] .
EPR of mitochondrial localization of Mito-CP
Detection of protein by western blotting
Daudi cells and PBMCs were treated under hypoxia and normoxia with and without Mito-CP. Cells were lysed using 1×RIPA buffer, and 1 mm PMSF (phenylmethylsulphonylfluoride) was added; then, the solution was kept on ice for 5 min. The cell lysates were centrifuged at 14,000 g for 10 min. in a cold centrifuge, and supernatant was stored at -20˚C after aliquoting as a small working-stock solution. Protein concentration was measured by the Bradford method. Aliquots of the lysate (40 μg of protein) were separated on 10% w/v sodium dodecyl sulfatepolyacrylamide gel and transferred onto a nitrocellulose membrane with a glycine transfer buffer (192 mM Glycine/25 mM Tris-
The membrane was transferred to 5% bovine serum albumin (BSA) in 1×TBS, to block the nonspecific site, and incubated overnight in a rocker at 4˚C. The various primaries used include rabbit monoclonal antibody Akt, p-Akt, AMPK, p-AMPK, the x-linked inhibitor of apoptosis protein (XIAP), Cytochrome c, cleaved PARP, and β-actin (Cell Signaling Technologies, Danvers, MA, USA), HIF-1α (Santa Cruz Biotechnology, Dallas, TX, USA). The membrane was incubated in a primary antibody solution (1:1000 dilution in a primary dilution buffer) overnight. Then, the membrane was washed thoroughly in 1×TBST and TBS for 30 min to remove any nonspecific bound antibodies. The membrane was incubated in a secondary antibody goat anti-rabbit IgG alkaline phosphatase (for HIF-1α) and goat anti-rabbit IgG horse radish peroxidase (for the other proteins) (Santa Cruz Biotechnology, Dallas, TX, USA) for 45 min. For developing, chromogenic NBT/BCIP (nitro blue tetrazolium/5-bromo-4-chloro-3-indolylphosphate) (Thermo Fisher Scientific, Rockford, IL, USA) for alkaline phosphatase secondary antibody and ECL (enhanced chemiluminescence) (GE Healthcare, Amersham, UK) for HRPconjugated secondary antibody were used. The band intensities of individual proteins were quantified and normalized with corresponding β-Actin band intensity using Image lab and Image studio lite ver. 5.2 software and arbitrary units with respect to control groups are represented as bar graphs.
Quantitative real-time polymerase chain reaction
Pro-apoptotic gene BCL2-associated X protein (BAX) was determined by RT-PCR (reverse transcription polymerase chain reaction). Total RNA (ribonucleic acid) was isolated from the Daudi cells and PBMCs under hypoxia and normoxia with and without Mito-CP using a Trizol reagent (Bangalore GeNei by Merck, Darmstadt, Germany). Primer-BLAST software was used to design the primers glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Sigma- GAPDH was taken as an internal control. cDNA was mixed with SYBR Green Master (Roche Diagnostics, Indianapolis, IN, USA), and the reaction volume was brought up to 10 μL with PCR-Grade water (Sigma-Aldrich, St. Louis, MO, USA) and analyzed using the Applied Biosystems StepOne Real-Time PCR instrument. Amplified products were analyzed using a melting curve analysis for each primer pair, and comparative threshold cycle data values were noted. Data were then analyzed for a fold change in expression using the formula 2 -ΔΔCT .
Statistical analysis
All data were presented as mean ± standard error (SEM) and repeated three to five times in each experiment independently. The statistical differences between groups were analyzed by two way ANOVA (analysis of variance) with Bonferroni Post-test in graph pad prism 5 software. P < 0.05 and P < 0.01 were considered statistically significant.
Results
Cytotoxic, antiproliferative and apopototic effects of Mito-CP in Daudi Cells and PBMCs
AlamarBlue dye was used to analyze cell viability and proliferation in Daudi cells and PBMCs. Daudi cells treated with Mito-CP showed a significant decrease 54% and 64% (P < 0.01) in cell viability under normoxia and hypoxia respectively " Fig 1A" . PBMCs treated with Mito-CP also showed a significant but less loss (12%-P<0.05) in cell viability under normoxia. Moreover, Mito-CP showed a significant protection against hypoxia induced decrease in cell viability in PBMC. In comparison to Mito-CP, Dec-TPP + alone treatment under hypoxia and normoxia in Daudi showed a weaker decrease in cell viability (28% and 23% respectively-P<0.05) in Daudi cells " Fig 1A" . levels between normoxia and hypoxia treatments. " Fig 3C" . An EPR spectra analysis was performed to determine the localization of Mito-CP in isolated mitochondria of Daudi cells and PBMCs, as the accumulation of Mito-CP correlates with the EPR signal intensity [16] . The EPR spectra analysis showed that there was no intensity in untreated Daudi cells and PBMCs. Further, it showed that, after 6 h of treatment, the signal intensity of Mito-CP was significantly higher (P<0.01) in Daudi cells than in PBMCs. Similarly, under hypoxia, the signal intensity of Mito-CP observed in the mitochondria of Daudi cells was significantly higher (P<0.01) than in the mitochondria of PBMCs, which proves there was much less accumulation in the PBMCs " Fig 3D and 3E". Effect of Mito-CP on pro-apoptotic BAX mRNA levels and HIF-1α protein levels
The expression levels of pro-apoptotic BAX mRNA, in Daudi cells, increased tenfold under hypoxia and increased significantly (P<0.05) under normoxia after Mito-CP treatment. However, in PBMCs, the expression levels in BAX mRNA decreased significantly (P<0.05) after treatment with Mito-CP, under both hypoxia and normoxia " Fig 4A" . Protein expression of HIF-1α in Daudi cells was analyzed by western blot. Both in Daudi cells and PBMC, the HIF-1α protein was expressed only in hypoxia but not in normoxia and Mito-CP treatment under hypoxia caused a significant decrease (P<0.05) in HIF-1α in both the cells when normalized to cellular β-Actin content " Fig 4B" .
Effects of Mito-CP on Akt mediated survival signaling and apoptotic markers
Western blots were used to analyze p-Akt, Akt, XIAP, PARP, and cytochrome C protein expression in Daudi cells and PBMCs. In Daudi cells, p-Akt had high expression levels under hypoxia, was downregulated significantly (P<0.05) in Mito-CP treatment under hypoxia, and also was downregulated significantly (P<0.05) in Mito-CP treatment under normoxia. But, in PBMCs, p-Akt's expression levels did not change under hypoxia or under normoxia in Mito-CP treatment, thus protecting PBMCs from apoptosis and enhancing survival. XIAP, the Akt pathway downstream protein, was regulated similarly to p-Akt in both Daudi cells and PBMCs. Apoptotic markers such as PARP and cytochrome C expression were significantly enhanced (P<0.01) with Mito-CP treatment in Daudi cells compared to PBMCs, under hypoxia and normoxia. The pathway expression was confirmed by blocking Akt signaling using the PI3K inhibitor wortmannin under hypoxia in Daudi cells and under normoxia in PBMCs " Fig 5A and 5B" . There was no effect on AKT phosphorylation levels by Dec-TPP + treatment in Daudi under hypoxia and normoxia. In PBMCs Dec-TPP + treatment did not show any significant decrease in AKT levels under normoxia and hypoxia. Dec-TPP + treatment under normoxia and hypoxia showed a significant increase (P<0.01) in phospho-AMPK/total-AMPK expression levels in Daudi cells than in PBMC's " Fig 6A and 6B ".
Discussion
In this study, we have shown for the first time that the anticancer property of the mitochondrially targeted antioxidant Mito-CP in the Burkitt lymphoma Daudi cell line is mediated through its effects on mitochondrial bioenergetics and antioxidant properties. Mito-CP consists of an alkyl chain linking its antioxidant nitroxide moiety to the lipophilic and cationic triphenylphosphonium (TPP) moiety. The cationic TPP moiety is lipophilic and can freely pass through the phospholipid bilayer of the plasma membrane and other organelles, without the requirement for a specific uptake transporter protein. This property of Mito-CP can be exploited to overcome multidrug resistance evolved by cancer cells against various chemotherapeutic drugs by elevating p-glycoprotein pumping, and MDR and ABCB (ATP-linked drug transporter) protein expression [17] [18] [19] [20] [21] [22] . The cells' negative plasma membrane potential (−30 mV to −60 mV) drives the movement of TPP from the extracellular space into the cytoplasmic Targeting mitochondria for cancer therapy compartment up to tenfold. TPP can further accumulate within the mitochondria up to several hundredfold due to the higher mitochondrial membrane potential (−140 mV to −180 mV) [23] . It has been determined that the increase in TPP accumulation within the mitochondria is approximately tenfold for every 60-mV increase in mitochondrial membrane potential [16] . Compared with PBMCs, Daudi cells exhibit a higher membrane potential under normoxic and hypoxic states, with peak values under hypoxia; as such, a selective localization of Mito-CP in Daudi cell mitochondria can be achieved, as is evident from the results of the EPR spectra analysis. Considering the alkyl chain between TPP + and nitroxide moiety, it has been shown that alkyl derivatives of TPP collapse the mitochondrial membrane potential and more effectively inhibit the respiratory chain than the equal concentration of carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP). Moreover, TPP + alkyl derivatives bind nonspecifically to the inner mitochondrial membrane, which results in a loss of membrane integrity and causes a breakdown of its insulating properties and impairment of the phospholipid milieu faced by respiratory complexes [24] . Thus, in addition to its selective localization toward cancer cell mitochondria, Mito-CP exhibits inhibitory effects on mitochondrial bioenergetics, as evidenced by studies on membrane potential and cellular ATP levels. Similar effects of Mito-CP on inhibiting the membrane potential of medullary carcinoma cell line has been shown [25] . The antioxidant property of Mito-CP involves both superoxide dismutase (SOD) and catalase mimetic activity. It essentially takes place in two steps: 1) conversion of superoxide (O 2 -) into H 2 O 2 by Mito-CP [16] , and 2) activation of catalase mimetic activity of heme proteins such as metmyoglobin (an Fe(III) form of myoglobin) by nitroxides resulting in H 2 O 2 dismutation accompanied by O 2 evolution [26] . In normoxic conditions, the levels of metmyoglobin are limited; thus, the slow-but-steady accumulation of H 2 O 2 could occur by the SOD activity of Mito-CP. This could account for the absence of changes in the H 2 O 2 levels in Daudi cells treated with Mito-CP under normoxia in our study. However, the significant reduction of H 2 O 2 levels after Mito-CP treatment under hypoxia can be correlated with the increased drug localization and levels of myoglobin under hypoxia [27] . In PBMCs, the effect of Mito-CP on H 2 O 2 levels was more pronounced due to its high dependency on mitochondrial-coupled respiration for ROS generation rather than NOX2-based ROS, which is elevated in Daudi cells. In this regard, inhibition of the electron flow itself has been shown to decrease ROS generation 5%O 2 ) and normoxia. P-AKT, AKT, P-AMPK, AMPK were measured by western blot. Β-actin was used to normalise of protein expression. (B) Densitometry analysis of P-AKT, AKT, P-AMPK, and AMPK were performed and the beta actin normalized P-AKT/Total-AKT and P-AMPK/Total-AMPK values were represented as bar graph. Data were obtained from three separate experiments and were expressed as by mean ± SEM. * and **, significantly different when compared to control p<0.05 and p<0.01 respectively.
https://doi.org/10.1371/journal.pone.0174546.g006
Targeting mitochondria for cancer therapy under conditions where NOX2-based ROS is not dominant. Thus, the effect of Mito-CP on cellular H 2 O 2 levels in PBMCs could be attributed to its combined effect on mitochondrial electron transport and its direct antioxidant scavenging properties. Moreover, the antioxidant scavenging by Mito-CP involves the generation of oxygen, which in turn could support the mitochondrial-dependent ATP synthesis as observed from our study on cellular ATP levels. This also corroborates earlier findings on the effect of Mito-CP in enhancing and irreversibly reducing oxygen consumption in normal and cancerous breast cancer cells, respectively [28] . Cellular ATP levels have been shown to play a decisive role in cell survival signaling mediated by Akt and AMPK phosphorylation. A Decrease in ATP levels have been shown to increase the activation phosphorylation of AMPK and subsequently decrease the activation phosphorylation of Akt [29] . Dephophorylation of Akt is done by two types of phosphatases, viz., PP2A and PHLPP1/2 (PH domain leucine rich repeat protein phosphatase). In conditions of availability, ATP competitively binds to phosphorylated Akt and forms a phosphataseshielding cage. This prevents phosphatase from executing its dephosphorylation reaction on Akt. Thus, ATP availability sustains Akt-mediated survival and apoptosis inhibition, even in the presence of active phosphatases [30] [31] [32] . In our study, we found that Mito-CP treatment decreased the phosphorylation of Akt and increased the phosphorylation of AMPK, which correlated with the decrease in ATP levels in Daudi cells under both hypoxia and normoxia. However, Mito-CP treatment in PBMCs did not affect the phosphorylation of Akt and AMPK, which correlated with its negligible effects on ATP levels.
In addition to ATP, an elevated ROS response is known to influence the Akt-mediated growth/survival pathway by its redox reaction with PP2A [33] . A key feature of this regulation is that PP2A's activity on Akt also requires reduced ATP levels to overcome the phosphataseshielding cage formed by ATP, as discussed previously. Thus, decreasing the ROS levels (such as H 2 O 2 ) alone is not a viable option for inhibiting cancer cell survival and inducing apoptosis unless it is coupled with inhibition of ATP production. Interestingly, Mito-CP fits this dual mode of action in cancer cells by decreasing H 2 O 2 levels via its antioxidant nitroxide moiety and reducing mitochondrial ATP production via its alkyl TPP + moiety. Moreover, Mito-CP's inhibitory effect on hypoxic adaptations in cancer cells (such as aerobic glycolysis mediated by HIF-1α [34, 35] can be correlated with its effects on Akt and H 2 O 2 , which are required for synthesis and stabilization of HIF-1α, respectively [36, 37] . This suggests a novel mode of action of Mito-CP in influencing the cancer survival signaling under both normoxic and hypoxic conditions in Daudi cells mediated by EBV. Direct support for this dual mechanism of Mito-CP comes from an earlier study with Dec-TPP, a control compound for Mito-CP, which lacks the carboxy proxyl moiety and, hence, the antioxidant property. It has been shown that Dec-TPP exhibits significant ATP reduction without inducing cytotoxicity in breast cancer cells [28] . However, a study comparing the effects Mito-CP and Mito-CP-acetamide, the nitroxide moiety of which had been modified into an acetamide, did not show any difference in cytotoxicity in pancreatic cancer cells [38] . Though not supporting a direct antioxidant mechanism, this study suggests an indirect antioxidant mechanism via NOX inhibition by a mitochondrially targeted antioxidant [39] , which was significant under conditions of cisplatin-induced oxidative stress but not under normal conditions [40] . Considering that acetamide derivatives have been shown to possess antioxidant properties [41] and NOX activity itself is directly activated by Akt-mediated phosphorylation [42] . Our studies with Dec-TPP also supports the essential role of antioxidant moiety for cytotoxic action of Mito-CP in Daudi cells. The dual mode of action of Mito-CP proposed in this work directly adds support to the above findings on Mito-CP's mechanism of cancer cytotoxicity.
Further, we confirmed that the Akt-mediated survival signaling cascade toward apoptosis regulation was also influenced by Mito-CP in Daudi cells under both hypoxia and normoxia. Specifically, Mito-CP caused a downregulation of the antiapoptotic factor XIAP; caused an upregulation of BAX expression and protein levels of cytochrome C; and cleaved PARP, which eventually contributed to apoptosis in Daudi cells. This mechanism was validated by treating Daudi cells and PBMCs with the Akt pathway inhibitor wortmannin, which showed similar effects as that of Mito-CP with respect to Akt-S473 phosphorylation and cleaved PARP levels.
In conclusion, this study has shown for the first time that Mito-CP selectively induces apoptosis in Daudi cells by mitochondrial potential dependent localization and downregulation of survival strategies mediated by Akt. The effects of Mito-CP on Akt in Daudi cells required both its antioxidant properties and mitochondrial bioenergetics "Fig 7" . This prompts the possibility for its evaluation and therapeutic application in cancers that arise from viral or mutagenic transformations similar to that occurring in Daudi cells by EBV. Moreover, Mito-CP can be evaluated for its suppression of EBV reactivation, which is associated with pathologies (such as infectious mononucleosis) and autoimmune diseases (such as rheumatoid arthritis and multiple sclerosis) and translated clinically in combination with other antiviral drugs.
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